Sorrentino S, Claessen BE, Chandiramani R, et al. - Analyzing data from four all-comers postapproval registries, researchers investigated the long-term adverse events in high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) with cobalt-chromium (CoCr) everolimus-eluting stent implantation. Presence of at least one of the following criteria led to the categorization of patients as HBR: age ≥ 75 years, history of major bleeding (MB), history of stroke, chronic oral anticoagulant use, chronic kidney disease (CKD), anemia, or thrombocytopenia. They identified 3,507 (33%) patients as HBR among 10,502 included patients. Outcomes revealed worse 4-year outcomes after PCI with CoCr everolimus-eluting stent among HBR patients vs the non-HBR population. A significant impact of both coronary thrombotic events and MB on subsequent risk of mortality was observed; this impact was irrespective of bleeding risk.